Treatment Information

Back

Kidney (Renal) Cancer treatment details. Chemotherapy.

University of Chicago, Chicago, Illinois, United States.

Survival: monthsCountry:United States
Toxiciy Grade:3City/State/Province:Chicago, Illinois
Treatments:ChemotherapyHospital:University of Chicago
Drugs:Journal:Link
Date:Aug 2002

Description:

Patients: This Phase II trial involved 12 patients with metastatic renal cell carcinoma; seven men and 5 women. The median age was 59. Eight of the patients had undergone a prior nephrectomy.

Treatment: The treatment consisted of administration of a chemotherapy drug, temozolomide (temodar).

Toxicity: Grade three toxicities included hematologic (anemia), fatigue, nausea, and vomiting.

Results: There were no responses and the authors concluded that temozolomide was not active against renal cell carcinoma.

Support: The study was supported in part by Schering-Plough, Inc. This company markets temozolomide (temodar).

Correspondence: W.M. Stadler, MD





Back